End-of-day quote
Taiwan S.E.
06:00:00 2024-07-15 pm EDT
|
5-day change
|
1st Jan Change
|
47.9
TWD
|
-0.93%
|
|
-3.23%
|
-10.13%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
3,115
|
4,198
|
3,999
|
3,888
|
6,453
|
5,383
|
Enterprise Value (EV)
1 |
3,412
|
4,280
|
4,214
|
4,002
|
6,460
|
5,710
|
P/E ratio
|
30.9
x
|
19.3
x
|
21.9
x
|
19.8
x
|
18.4
x
|
27.2
x
|
Yield
|
3.89%
|
4.05%
|
4.04%
|
4.68%
|
3.6%
|
3.75%
|
Capitalization / Revenue
|
2.02
x
|
2.38
x
|
2.28
x
|
2.18
x
|
3.33
x
|
2.5
x
|
EV / Revenue
|
2.22
x
|
2.43
x
|
2.4
x
|
2.25
x
|
3.33
x
|
2.66
x
|
EV / EBITDA
|
10.6
x
|
9.65
x
|
10.3
x
|
9.24
x
|
13
x
|
13
x
|
EV / FCF
|
27.7
x
|
18.5
x
|
468
x
|
12
x
|
33.5
x
|
37.9
x
|
FCF Yield
|
3.61%
|
5.41%
|
0.21%
|
8.31%
|
2.99%
|
2.64%
|
Price to Book
|
1.5
x
|
1.94
x
|
1.81
x
|
1.74
x
|
2.68
x
|
2.26
x
|
Nbr of stocks (in thousands)
|
100,988
|
100,073
|
100,989
|
100,989
|
100,989
|
100,989
|
Reference price
2 |
30.85
|
41.95
|
39.60
|
38.50
|
63.90
|
53.30
|
Announcement Date
|
4/1/19
|
3/20/20
|
3/24/21
|
3/10/22
|
3/6/23
|
3/26/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,539
|
1,762
|
1,755
|
1,780
|
1,940
|
2,150
|
EBITDA
1 |
323.2
|
443.5
|
409.4
|
433.3
|
496.7
|
440.8
|
EBIT
1 |
126.8
|
251.1
|
224.9
|
254.5
|
321.7
|
259.8
|
Operating Margin
|
8.24%
|
14.25%
|
12.82%
|
14.3%
|
16.58%
|
12.08%
|
Earnings before Tax (EBT)
1 |
117.7
|
250.8
|
223.6
|
234.8
|
410.6
|
213.7
|
Net income
1 |
101.2
|
217.4
|
183.4
|
196.1
|
352
|
198.4
|
Net margin
|
6.58%
|
12.34%
|
10.45%
|
11.02%
|
18.14%
|
9.23%
|
EPS
2 |
1.000
|
2.170
|
1.810
|
1.940
|
3.480
|
1.960
|
Free Cash Flow
1 |
123.2
|
231.8
|
9.009
|
332.7
|
193
|
150.6
|
FCF margin
|
8.01%
|
13.15%
|
0.51%
|
18.69%
|
9.94%
|
7%
|
FCF Conversion (EBITDA)
|
38.12%
|
52.26%
|
2.2%
|
76.79%
|
38.85%
|
34.17%
|
FCF Conversion (Net income)
|
121.71%
|
106.58%
|
4.91%
|
169.67%
|
54.82%
|
75.91%
|
Dividend per Share
2 |
1.200
|
1.700
|
1.600
|
1.800
|
2.300
|
2.000
|
Announcement Date
|
4/1/19
|
3/20/20
|
3/24/21
|
3/10/22
|
3/6/23
|
3/26/24
|
Fiscal Period: December |
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
---|
Net sales
1 |
375.8
|
472.9
|
-
|
601
|
EBITDA
|
-
|
-
|
-
|
-
|
EBIT
1 |
32.2
|
93.76
|
-
|
122
|
Operating Margin
|
8.57%
|
19.83%
|
-
|
20.31%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
74.6
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
0.7400
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/4/22
|
8/8/22
|
11/4/22
|
3/6/23
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
297
|
82.3
|
215
|
114
|
6.62
|
327
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.9188
x
|
0.1856
x
|
0.5252
x
|
0.264
x
|
0.0133
x
|
0.7421
x
|
Free Cash Flow
1 |
123
|
232
|
9.01
|
333
|
193
|
151
|
ROE (net income / shareholders' equity)
|
4.82%
|
10.3%
|
8.35%
|
8.82%
|
15.1%
|
8.29%
|
ROA (Net income/ Total Assets)
|
2.49%
|
4.97%
|
4.29%
|
4.76%
|
5.73%
|
4.37%
|
Assets
1 |
4,063
|
4,375
|
4,271
|
4,124
|
6,140
|
4,545
|
Book Value Per Share
2 |
20.50
|
21.70
|
21.80
|
22.20
|
23.90
|
23.50
|
Cash Flow per Share
2 |
1.760
|
3.880
|
2.640
|
4.130
|
3.970
|
3.750
|
Capex
1 |
155
|
75
|
90.1
|
156
|
93.8
|
298
|
Capex / Sales
|
10.1%
|
4.25%
|
5.14%
|
8.77%
|
4.84%
|
13.84%
|
Announcement Date
|
4/1/19
|
3/20/20
|
3/24/21
|
3/10/22
|
3/6/23
|
3/26/24
|
|
1st Jan change
|
Capi.
|
---|
| -10.13% | 150M | | +61.53% | 856B | | +38.95% | 631B | | -3.66% | 359B | | +15.06% | 325B | | +9.18% | 297B | | +5.89% | 234B | | +16.53% | 226B | | +15.67% | 177B | | +2.47% | 165B |
Other Pharmaceuticals
|